Search for: "TEVA PHARMACEUTICAL INDUSTRIES, LTD."
Results 1 - 20 of 100
Sorted by Relevance | Sort by
Date
7 Aug 1:54 pm
On Wednesday, Teva Pharmaceutical Industries Ltd. sued Merrill Lynch & Co., a Bank
of America Corp. unit. The pharmaceutical company's securities fraud lawsuit accuses the brokerage firm of making misrepresentations that
resulted in its purchase of $273 million in ARS. Merrill Lynch underwrote the securities that Teva bought. A day later, Seneca Gaming Corp.
filed its own lawsuit against Merrill Lynch. The complaint is over a $5 million ...
26 Aug 9:59 pm
... -in-part and affirmed-in-part an order by the District Court for the District of New Jersey granting summary judgment of invalidity of U.S. Reissued Patent No. 39,221 based on
anticipation and obviousness. Plaintiff-Appellant Ortho-McNeil Pharmaceutical, Inc. owns the '221 patent, which relates to a tramadol and
acetaminophen composition for use in prescription pain relief. Ortho first claimed this composition in U.S. Patent No. 5,336,691, and after receiving FDA approval, began marketing a ...
20 Aug 1:06 pm
... U.S. District Court Judge Garrett Brown rejected the argument made by Teva Pharmaceuticals Industries Ltd. that the
patent covering the main ingredient in Merck & Co.'s asthma ... at Google patents with this link: U.S. Patent No. 5,565,473. Teva is the
world's largest generic drug maker and has a 22% market share ... Waxman Act, passed by Congress in 1984, gives generic drug companies an incentive to challenge pharmaceutical patents. According to the Hatch-Waxman Act, if a generic drug maker is able ...
26 Jan, 2007 6:18 pm
Business Wire reported on January 24, 2007: Teva Pharmaceutical Industries Ltd.
(NASDAQ: TEVA) announced today that it has filed infringement complaints against a number of finished dose companies which manufacture
sertraline hydrochloride, AB rated to Zoloft®, and their active pharmaceutical ingredient suppliers. Teva filed the complaints in the United States District Courts of New Jersey, Delaware, Southern District New York, and Maryland ...
18 Oct 5:42 pm
Teva Pharmaceutical Industries Ltd. issued a press release last week discussing the
abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan ... Pharmaceutical Companies, Inc. to delay generic competition to Solvay's branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than $400 million. "At a time [...]... Senate Bill Would Prevent Reverse Pharma PaymentsThe Patent ...
26 Jun, 2007 10:48 pm
... these prescription drugs, the false pricing reports caused Medicaid to overpay by millions of dollars for these drugs. Ven-a-Care, an industry whistleblower, disclosed the
scheme. The pharma companies named by the Attorney General are: • Mylan Laboratories Inc. of Pennsylvania (with national ... Inc., Sicor Pharmaceuticals Inc., Teva Novopharm Inc. and Teva Pharmaceutical Industries,
Ltd.). We applaud the Texas Attorney General's Office once again for leading the fight against health care fraud.
5 Sep, 2007 6:17 am
... s decision to block sales of generic forms of the drug made by Ivax (Teva Pharmaceutical
Industries Ltd) and Cipla Ltd. The CAFC did alter D. Del.'s injunction so that it only applies to escitalopram oxalate, the active ingredient in Lexapro. The CAFC
decision gets into issues with ... to IVAX without discussing evidence favorable to Forest. There is an analysis of a broadening reissue. [Recall: Teva Pharmaceuticals (TEVA) said in July 2005 that it would buy U.S. rival Ivax (IVX) for ...
12 Jul, 2008 2:26 am
... 11, 2008 Teva press release appearing at PharmaLive: Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today commented on Momenta Pharmaceuticals,
Inc./Sandoz Inc.'s announcement regarding the filing of a Abbreviated ... a Paragraph IV certification for COPAXONE(R) (glatiramer acetate), a leading multiple sclerosis therapy.
Teva expects to receive Momenta/Sandoz's Paragraph IV certification notice referring to Teva's U.S.
Patent Nos. 5,981,589, 6,054,430, 6,342,476, 6,362,161, 6,620,847, 6,939,539 ...
22 Jul, 2008 3:36 am
By Sherri Oslick -- In a transaction merging two major players in the generic pharmaceutical arena, Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced late last week
that they have entered into an agreement by which ... transaction is expected to close by the end of 2008, pending antitrust clearance and Barr stockholder approval. Barr
Pharmaceuticals, Inc., a holding company, operates through subsidiaries Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc., and PLIVA d.d ...
7 Sep, 2007 3:03 am
... Lexapro, but Friday's a brand new day and stock traders are already looking to Teva's chances on launching a generic version of Wyeth's
Protonix. AP reported on Friday, Sept. 7: Teva Pharmaceutical Industries Ltd. shares
edged higher Friday as investors wondered if the company will soon ... U.S. District Court rejected Wyeth's request for an injunction that would have kept Teva from selling its version of the heartburn drug until a patent dispute between the companies was resolved. Teva
...
19 Jan 2:56 pm
Boston, Massachusetts- According to a January 5, 2009 report by Dow Jones Newswires, Teva Pharmaceutical Industries Ltd. (TEVA) paid $7 million to the Massachusetts Medicaid program to settle
a False Claims Act case pending in federal court. The allegations ... into drug companies that have allegedly taken advantage of the Medicaid system. To learn more go here. or if you
have information about Pharmaceutical Fraud contact Nolan & Auerbach P.A. False Claims Act, Medicare fraud, Pharma Fraud
30 Jun 7:03 pm
Teva Pharmaceuticals USA, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., is making a full-court press on getting the word out on the need for follow-on biologics. In its "Year of
Affordable Healthcare" campaign, Teva is putting put together videos to argue for generics, just as the White House is making its position
known on the need for biogenerics (read: need for lower costs). The ...
2 Jul 6:01 pm
... from a Thursday, July 02, 2009 press release at Webwire: Bayer Schering Pharma AG, Germany and Bayer HealthCare Pharmaceuticals Inc. together with Schering Corporation have
filed a patent infringement lawsuit in the U.S. Federal Court in the District of Delaware against Teva Pharmaceuticals USA, Inc. and
Teva Pharmaceutical Industries, Ltd.. The lawsuit concerns Teva's application to the FDA for approval to market a generic form of Levitra®, Bayer ...
24 Jul 1:31 am
... &J spokesman Greg Panico: "This settlement compensates us for loss caused by their [Teva's] at-risk launch and recognizes the patent is
valid and enforceable," suggesting that ... Teva had issued a press release on 1 July 09: Teva
Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and
Drug Administration ... twelve months that ended March 31, 2009 based on IMS sales data. Teva is currently involved in patent litigation
concerning this product in the U.S. District Court ...
19 Aug, 2008 11:07 am
... on this,''' said Barrett, now vice president of government affairs in Washington for generic-drug maker Teva Pharmaceutical Industries Ltd. of Petah Tikva, Israel. A narrower version of the measure, allowing quicker access to generics in certain ...
with the drug industry views McCain as a foe. Doug Badger, a lobbyist with the Nickles Group in Washington, which represents pharmaceutical companies, said a McCain presidency would be better for drugmakers than an Obama administration. ``I don't perceive ...
21 May, 2007 8:31 am
As reported today, May 21, 2007, at Business Wire: Teva Pharmaceutical Industries Ltd.
(Nasdaq:TEVA) announces that on May 18, 2007 the U.S. Food and Drug ... with Novartis' pending patent infringement action, an emergency request
for a temporary order restraining Teva's launch and scheduled a hearing for May 21, 2007 at 11:00 ... file an Abbreviated New Drug Application
(ANDA) with a Paragraph IV patent certification, Teva has been awarded 180 days marketing exclusivity for this product. See the full ...
27 Jul 3:32 am
On July 24, 2009, Teva issued the following statement at Business Wire: Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into a definitive
agreement with Ortho-McNeil-Janssen to settle the patent infringement ... of the settlement, Teva will obtain a release for past sales of its
generic product, in exchange for an undisclosed royalty payment. Teva also will obtain a license to re-enter the market on December 31, 2015,
or earlier in certain circumstances. The ...
25 Sep, 2008 4:23 am
By Donald Zuhn -- Last week, Teva Pharmaceutical Industries Ltd. announced that the
European Commission's Directorate General for Enterprise and Industry has granted the company a marketing authorization for its human granulocyte colony stimulating factor
(G-CSF) product. Teva had earlier received a favorable opinion for its G-CSF product from the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines ...
26 Nov, 2007 9:02 pm
By Baltazar Gomez -- Last month, Astellas Pharma Inc., King Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. announced that U.S. subsidiaries of Astellas, along with Item Development AB and King have signed settlement
agreements with respect to U.S. Patent Nos. 5,731,296 and 5,070,877. The lawsuits involving the '296 and '877...
9 Feb, 2007 11:37 am
By Christopher P. Singer In a February 9, 2007 press release, Sanofi-Aventis announced that it has lost its patent infringement suit against generic drugmakers Amphastar
Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd., filed in the U.S.
District Court for the Central District of California. The suit relates to Sanofi-Aventis' blockbuster...
Search on: Blawgs.FM | BlawgSearch Google
Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!